Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials.

However, although the insulin or sulphonylurea-based intensified glucose-control treatment was effective in reducing the risk of major microvascular endpoints, the effects on CVD risk were modest and did not reach statistical significance. 2 Recent large clinical trials (often referred to as “megatrials”), the Action in Diabetes and Vascular Disease (ADVANCE), 3 Action to Control Cardiovascular Risk in Diabetes (ACCORD), 4 and the Veterans Affairs Diabetes Trial (VADT), 5 reported no significant decrease in primary cardiovascular endpoints with intensive glucose control.

also in 111,027 other papers